CytomX Therapeutics, Inc. Depreciation
CytomX Therapeutics, Inc. (CTMX) reported Depreciation of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-16
- CytomX Therapeutics, Inc. depreciation for the quarter ending 2017-12-31 was $400.00K, a 20.00% decline year-over-year.
- CytomX Therapeutics, Inc. depreciation for the quarter ending 2017-09-30 was $368.00K, a 16.93% decline year-over-year.
- CytomX Therapeutics, Inc. depreciation for the quarter ending 2016-12-31 was $500.00K.
- CytomX Therapeutics, Inc. depreciation for the quarter ending 2016-09-30 was $443.00K.
- CytomX Therapeutics, Inc. depreciation for fiscal 2025 was $1.20M, a 25.00% decline from fiscal 2024.
- CytomX Therapeutics, Inc. depreciation for fiscal 2024 was $1.60M, a 20.00% decline from fiscal 2023.
- CytomX Therapeutics, Inc. depreciation for fiscal 2023 was $2.00M, a 13.04% decline from fiscal 2022.
- CytomX Therapeutics, Inc. depreciation for fiscal 2022 was $2.30M, a 11.54% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.20M 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $1.60M 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $2.00M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $2.30M 10-K · filed 2024-03-11 | |||
| 2021-12-31 | $2.60M 10-K/A · filed 2023-03-27 | |||
| 2020-12-31 | $2.40M 10-K/A · filed 2023-03-27 | |||
| 2019-12-31 | $2.50M 10-K/A · filed 2023-03-27 | |||
| 2018-12-31 | $1.70M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $768.00K derived: sum of 2 quarters · filed 2020-02-27 | $1.50M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $368.00K 10-Q · filed 2017-11-07 | $1.10M 10-Q · filed 2017-11-07 | ||
| 2016-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $943.00K derived: sum of 2 quarters · filed 2019-02-27 | $1.70M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $443.00K 10-Q · filed 2017-11-07 | $1.20M 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $1.20M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |